Last edition
News about "Bayer"
Alvotech Reaches Global Settlement on Eylea Biosimilar
The settlement enables Alvotech and its partners to launch the biosimilar from January 1, 2026 in the UK and Canada, from May 1, 2026 in the EEA and other markets outside the US, and in Japan from May 2026 for select indications, expanding to all approved indications from November 1, 2026.
Bayer | 30/01/2026 | By News Bureau | 135
Bayer to Showcase Low-Dose MRI Contrast Innovation at ECR 2026
Bayer brings next-generation contrast agents and smart radiology solutions to ECR 2026, spotlighting progress in low-dose MRI imaging and clinical innovation.
Bayer | 28/01/2026 | By News Bureau | 144
FDA Grants Orphan Drug Status to BlueRock's OpCT-001
The ODD supports the clinical development of OpCT-001, the first iPSC-derived investigational cell therapy to enter human trials for Retinitis Pigmentosa (RP), a common inherited retinal disease marked by progressive loss of photoreceptor cells.
Bayer | 23/01/2026 | By News Bureau | 119
Bayer and VUMC Partner to Advance Cardiovascular and Kidney Therapies
The collaboration will focus initially on cardiovascular and kidney diseases, combining Bayer’s drug development expertise with Vanderbilt University Medical Center’s extensive data resources to generate data-driven insights and accelerate the discovery and development of new therapies addressing significant unmet medical needs.
Bayer | 21/01/2026 | By News Bureau
Bayer to Enter Molecular Imaging, Acquires Pan-Amyloid Radiotracers from Attralus
By acquiring AT-01 and AT-05 from Attralus, Bayer strengthens its molecular imaging and cardiovascular precision medicine portfolio, targeting earlier and more accurate diagnosis of amyloidosis.
Bayer | 14/01/2026 | By News Bureau | 111
Bayer Secures Japanese Approval for Finerenone
Bayer has received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for Finerenone (Kerendia), a non-steroidal, selective mineralocorticoid receptor antagonist, for the treatment of adult patients with chronic heart failure with mildly reduced or preserved Left Ventricular Ejection Fraction (LVEF).
Bayer | 23/12/2025 | By News Bureau | 217
Bayer Warns of Higher 2025 Earnings Impact from Lawsuits and Restructuring Costs
The German life sciences company now expects special items to reduce its earnings before interest, tax, depreciation, and amortisation (EBITDA) by between EUR 3.5 billion and EUR 4.0 billion, higher than the earlier forecast of EUR 2.5 billion to EUR 3.5 billion.
Bayer | 13/11/2025 | By Darshana | 628
WHO and Bayer Renew Partnership to Combat NTDs
The World Health Organization (WHO) and Bayer AG have renewed their partnership to combat Chagas disease, sleeping sickness, and taeniasis, with Bayer pledging USD 9.45 million to support WHO’s efforts through 2030.
Bayer | 06/11/2025 | By Dineshwori | 198
Bayer and Kumquat Biosciences have begun a Phase-I trial of their KRAS G12D inhibitor targeting KRAS-mutated tumors, further bolstering Bayer’s precision oncology pipeline across pancreatic, colorectal, and lung cancers.
Bayer | 11/10/2025 | By Dineshwori | 514
The first participant has been dosed in the pivotal Phase III exPDite-2 trial of bemdaneprocel, an investigational cell therapy, while the first European participants have been enrolled in REGENERATE-PD, a Phase II trial of the gene therapy AB-1005.
Bayer | 23/09/2025 | By Darshana | 252
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy